Concepedia

Phung Bondiskey

PB

6

Publications

224

Citations

6

H-Index

2010

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Thomas Jefferson University

MSD (Belgium)

Phung Bondiskey is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacotherapy, and pharmacology.

Top concepts

Publications per year

2010–2020

6

Publications

6

Hypersensitivity incidence after sugammadex administration in healthy subjects: a randomised controlled trial

K. Chris Min, Phung Bondiskey, Valerie Schulz et al. · British Journal of Anaesthesia · 2018 · 62 citations

, , +9

Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study

Kerri A. Schoedel, Hong Sun, Edward M. Sellers et al. · Journal of Clinical Psychopharmacology · 2016 · 40 citations

Discovery of 4,4-Disubstituted Quinazolin-2-ones as T-Type Calcium Channel Antagonists

James C. Barrow, Kenneth E. Rittle, Thomas S. Reger et al. · ACS Medicinal Chemistry Letters · 2010 · 38 citations

, , +17

Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults

K. Chris Min, Walter K. Kraft, Phung Bondiskey et al. · Clinical and Translational Science · 2020 · 35 citations · Full text

, , +15

Discovery and expanded SAR of 4,4-disubstituted quinazolin-2-ones as potent T-type calcium channel antagonists

Kelly-Ann S. Schlegel, Zhi-Qiang Yang, Thomas S. Reger et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 26 citations

, , +7

Rows per page

1–5 of 6